TQ Therapeutics
Biotechnology company developing a modular, automated extracorporeal platform to generate autologous cell therapies that are transiently or stably genetically modified ex vivo and function in vivo. Focus areas include affinity-based cell selection, short-turnaround point-of-care processing, non-viral and viral transfection approaches, and technologies to enable decentralized, scalable delivery of cell & gene therapies.
Industries
Nr. of Employees
small (1-50)
TQ Therapeutics
Fraunhoferstr. 1, 82152 Planegg, Germany
Products
Modular cell processing workflows (ultra‑short and pro variants)
Two process variants for extracorporeal T cell processing: an ultra‑short workflow using transient mRNA‑LNP modification and a PRO workflow supporting activation and viral or non‑viral genetic modification options.
Affinity‑based cell selection module
Closed, automated cell isolation module providing fast, residual‑free positive selection of target immune cells with extensible marker library.
Controlled T cell activation reagent
A multicomponent activation reagent designed for automated systems that provides adjustable stimulation and rapid signal termination for downstream removal.
Modular cell processing workflows (ultra‑short and pro variants)
Two process variants for extracorporeal T cell processing: an ultra‑short workflow using transient mRNA‑LNP modification and a PRO workflow supporting activation and viral or non‑viral genetic modification options.
Affinity‑based cell selection module
Closed, automated cell isolation module providing fast, residual‑free positive selection of target immune cells with extensible marker library.
Controlled T cell activation reagent
A multicomponent activation reagent designed for automated systems that provides adjustable stimulation and rapid signal termination for downstream removal.
Services
Platform services to isolate, activate, genetically modify, and return autologous target cells at or near the patient, using automated, closed workflows.
Research collaborations to integrate external LNP and other enabling technologies into a rapid extracorporeal cell therapy process.
Platform services to isolate, activate, genetically modify, and return autologous target cells at or near the patient, using automated, closed workflows.
Research collaborations to integrate external LNP and other enabling technologies into a rapid extracorporeal cell therapy process.
Expertise Areas
- Automated point‑of‑care cell therapy manufacturing
- Affinity‑based cell selection and immunoaffinity chromatography
- mRNA‑LNP non‑viral transfection for cell therapies
- Viral vector and genome editing (CRISPR) integration strategies
Key Technologies
- Extracorporeal cell modification workflows
- Affinity column cell selection / immunoaffinity chromatography
- mRNA lipid nanoparticle (LNP) delivery
- Viral vector delivery
News & Updates
Announcement of acquisition of a cell therapy subsidiary to broaden access to intellectual property and license agreements supporting platform development.
Contribution of proprietary affinity‑based cell selection technology to an EU‑backed consortium developing an automated hospital‑based CAR‑T manufacturing platform targeting point‑of‑care production within 24 hours.
Research collaboration with an mRNA‑LNP platform provider to evaluate combining LNP delivery with a rapid extracorporeal cell therapy process for non‑viral transfection.
Publication describing automated cell chromatography methods compatible with GMP‑compliant cell isolation and activation.
Publication on technologies for controlled T cell activation relevant to automated manufacturing systems.
Announcement of acquisition of a cell therapy subsidiary to broaden access to intellectual property and license agreements supporting platform development.
Contribution of proprietary affinity‑based cell selection technology to an EU‑backed consortium developing an automated hospital‑based CAR‑T manufacturing platform targeting point‑of‑care production within 24 hours.
Research collaboration with an mRNA‑LNP platform provider to evaluate combining LNP delivery with a rapid extracorporeal cell therapy process for non‑viral transfection.
Publication describing automated cell chromatography methods compatible with GMP‑compliant cell isolation and activation.
Publication on technologies for controlled T cell activation relevant to automated manufacturing systems.